Gazyva Wins First-Ever FDA Approval for Primary Membranous Nephropathy
RHHBY sits 35% above its 52-week low of $44.57 on light trading volume (0.4× avg).
Summary
The FDA approved Gazyva (obinutuzumab) for adults with primary membranous nephropathy at risk of progression, making it the first and only approved therapy for the disease. The decision rests on the Phase III MAJESTY trial, where 36.1% of patients on Gazyva hit complete remission of proteinuria at two years versus 5.7% on tacrolimus. This is Gazyva's third FDA approval in immune-mediated kidney disease, after idiopathic nephrotic syndrome and lupus nephritis, and it extends the franchise into a rare disease with an estimated US incidence of 1.2 per 100,000 people per year. The label expansion is incremental revenue for a company of Roche's size, but it reinforces Genentech's kidney-disease franchise and follows a run of positive regulatory news including the October Enspryng approval in thyroid eye disease. The FDA is also reviewing Gazyva for systemic lupus erythematosus with a decision expected by December 2026, and CHMP recently backed the SLE indication in Europe.
At the time of this announcement, RHHBY was trading at $60.30 on OTC in the Life Sciences sector, with a market capitalization of approximately $384.6B. The 52-week trading range was $44.57 to $61.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.